Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Cleveland Clinic · University of Cambridge · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,196
total citations
- FWCI
- 55.39
- Percentile
- 100%
- References
- 39
Citations per year
Authors
18- JCJeffrey CohenCorresponding
Cleveland Clinic
- ACAlasdair Coles
University of Cambridge
- DLDouglas L. Arnold
McGill University, Montreal Neurological Institute and Hospital, NeuroRx Research (Canada)
- CCChristian Confavreux
Hospices Civils de Lyon, Université Claude Bernard Lyon 1
- EFEdward Fox
Central Texas Neurology Consultants
Topics & keywords
Topics
Keywords
- Alemtuzumab
- Medicine
- Interferon beta-1a
- Multiple sclerosis
- Internal medicine
- CD52
- Clinical endpoint
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.